PL8177 Demonstrates Therapeutic Effects in Inflammatory Conditions

CRANBURY, N.J., Jan. 10, 2023. Palatin Technologies, Inc. a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced Frontiers in Immunology...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials